论文部分内容阅读
目的:探讨多西他赛联合顺铂二线治疗老年人晚期非小细胞肺癌的有效性和安全性。方法:选取胶州市人民医院2017年1月至2019年12月收治的需行二线治疗的老年人晚期非小细胞肺癌120例为观察对象。采用随机数字表法分为观察组和对照组，每组60例。对照组患者接受多西他赛治疗，观察组患者接受多西他赛联合顺铂治疗。比较两组临床疗效及并发症发生情况。结果:化疗后，观察组化疗近期总有效率［70.00%（42/60）］高于对照组［33.33%（20/60）］，差异有统计学意义（χn 2=16.15，n P < 0.05）；观察组血清癌胚抗原（CEA）［（22.57±3.22）μg/L］、糖蛋白抗原125（CA125）［（48.61±5.42）U/mL］、细胞角蛋白19片段抗原21-1（CY211）［（10.61±1.64）μg/L］较对照组［（35.52±4.46）μg/L、（69.64±7.75）U/mL、（14.26±1.95）μg/L］均明显下降，差异均有统计学意义（ n t=18.23、17.22、11.09，均 n P <0.001）；观察组CD n 3+［（78.31±8.09）%］、CDn 4+［（48.63±5.74）%］较对照组［（69.58±7.26）%、（39.82±4.25）%］均明显增高，CDn 8+［（22.64±3.82）%］较对照组［（26.77±4.01）%］明显下降，差异均有统计学意义（n t=-6.22、-9.55、5.77，均 n P <0.001）；观察组1年生存情况显著优于对照组（χ n 2=4.05，n P 0.05）。n 结论:多西他赛联合顺铂二线治疗老年人晚期非小细胞肺癌可显著提高疗效，降低机体血清肿瘤标志物水平，增强免疫功能，改善患者1年生存情况，安全可靠，值得临床推广。“,”Objective:To investigate the effectiveness and safety of docetaxel combined with cisplatin in the second-line treatment of advanced non-small cell lung cancer in older adult patients.Methods:120 older adult patients with advanced non-small cell lung cancer who received second-line treatment in Jiaozhou People\'s Hospital from January 2017 to December 2019 were included in this study. They were randomly assigned to undergo treatment with docetaxel (control group, n n = 60) or docetaxel + cisplatin (observation group, n n = 60). Clinical efficacy and complications were compared between the two groups.n Results:After chemotherapy, short-term total response rate was significantly higher in the observation group than in the control group [70.00% (42/60) n vs. 33.33% (20/60), n χ2 = 16.15, n P < 0.05]. Serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19-fragment CYFRA21-1 were (22.57 ± 3.22) μg/L, (48.61 ± 5.42) U/mL, (10.61 ± 1.64) μg/L, respectively in the observation group, which were significantly lower than those in the control group [(35.52 ± 4.46) μg/L, (69.64 ± 7.75) U/mL, (14.26 ± 1.95) μg/L, n t = 18.23, 17.22, 11.09, all n P < 0.001]. The percentages of CD n 3+ and CDn 4+ cells were (78.31 ± 8.09)% and (48.63 ± 5.74)%, respectively in the observation group, which were significantly higher than those in the control group [(69.58 ± 7.26)%, (39.82 ± 4.25)%, n t = -6.22, -9.55, both n P < 0.001]. The percentage of CD n 8+ was significantly lower in the observation group than in the control group [(22.64 ± 3.82)% n vs. (26.77 ± 4.01)%, n t = 5.77, n P < 0.001). The 1-year survival was significantly higher in the observation group than in the control group ( n χ2 = 4.05, n P 0.05).n Conclusion:Docetaxel combined with cisplatin is highly effective on advanced non-small cell lung cancer in older adult patients. The combined therapy can decrease serum tumor marker levels, improve immune function, and increase 1-year survival rate. It is safe and provides reliable efficacy and thereby is worthy of clinical promotion.